Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax

Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies

Amgen logo
AmgenAMGN
——
Arcus Biosciences logo
Arcus BiosciencesRCUS
——
Nuvation Bio logo
Nuvation BioNUVB
——
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
——
Summit Therapeutics logo
Summit TherapeuticsSMMT
——
Vir Biotechnology, Inc. logo
Vir Biotechnology, Inc.VIR
——

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
Bicara Therapeutics (BCAX) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $245K in Q1 2026.